{"id":31804,"date":"2025-04-15T13:04:59","date_gmt":"2025-04-15T05:04:59","guid":{"rendered":"https:\/\/flcube.com\/?p=31804"},"modified":"2025-04-15T13:05:00","modified_gmt":"2025-04-15T05:05:00","slug":"novlead-biotech-secures-series-c-financing-to-expand-no-inhalation-therapy-device-production","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=31804","title":{"rendered":"Novlead Biotech Secures Series C Financing to Expand NO Inhalation Therapy Device Production"},"content":{"rendered":"\n

Novlead Biotech, a Nanjing-based specialist in nitric oxide (NO) gas detection and treatment, has secured “hundreds of millions” of renminbi in a Series C financing round. Led by D&T Capital, the funding round included contributions from Yangzhou Guojin Investment, Zhongshan Investment Holding, Triwise Capital, Efung Capital, and Xingxiang Investment. The proceeds will be allocated toward expanding manufacturing capacity, commercial promotion, and overseas business development for its portable NO inhalation therapy device, as well as advancing its innovative pipeline centered on NO release and generation technology.<\/p>\n\n\n\n

Funding and Strategic Allocation<\/strong>
The funds raised will primarily support the expansion of Novlead\u2019s manufacturing capabilities to meet growing demand for its portable NO inhalation therapy device. Additionally, the company plans to intensify commercialization efforts and explore international markets, leveraging its technological advantages in NO-based therapies. The investment will also fuel the development of next-generation products and innovative pipelines, further solidifying Novlead\u2019s position as a leader in the field.<\/p>\n\n\n\n

Product Innovation and Market Adoption<\/strong>
Novlead\u2019s flagship product, the INOwill portable NO inhalation therapy device, is a Category III medical device approved for marketing in China in 2022. Notably, INOwill is designed without a steel cylinder, offering significant advantages in convenience, safety, and effectiveness. Since its launch, the device has been rapidly adopted by hundreds of hospitals both domestically and internationally, finding applications in critical departments such as neonatal ICUs, adult ICUs, and cardiac surgery units.<\/p>\n\n\n\n

Company Background and Vision<\/strong>
Founded in 2018, Novlead Biotech has established itself as a pioneer in NO gas detection and therapeutic applications. With a strong focus on innovation and patient-centric solutions, the company continues to push the boundaries of NO technology, aiming to transform treatment paradigms in respiratory and critical care medicine.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Novlead Biotech, a Nanjing-based specialist in nitric oxide (NO) gas detection and treatment, has secured…<\/p>\n","protected":false},"author":1,"featured_media":31805,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[20,2715],"class_list":["post-31804","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-finance","tag-novlead-biotech"],"yoast_head":"\nNovlead Biotech Secures Series C Financing to Expand NO Inhalation Therapy Device Production - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novlead Biotech, a Nanjing-based specialist in nitric oxide (NO) gas detection and treatment, has secured "hundreds of millions" of renminbi in a Series C financing round. Led by D&T Capital, the funding round included contributions from Yangzhou Guojin Investment, Zhongshan Investment Holding, Triwise Capital, Efung Capital, and Xingxiang Investment. The proceeds will be allocated toward expanding manufacturing capacity, commercial promotion, and overseas business development for its portable NO inhalation therapy device, as well as advancing its innovative pipeline centered on NO release and generation technology.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=31804\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novlead Biotech Secures Series C Financing to Expand NO Inhalation Therapy Device Production\" \/>\n<meta property=\"og:description\" content=\"Novlead Biotech, a Nanjing-based specialist in nitric oxide (NO) gas detection and treatment, has secured "hundreds of millions" of renminbi in a Series C financing round. Led by D&T Capital, the funding round included contributions from Yangzhou Guojin Investment, Zhongshan Investment Holding, Triwise Capital, Efung Capital, and Xingxiang Investment. The proceeds will be allocated toward expanding manufacturing capacity, commercial promotion, and overseas business development for its portable NO inhalation therapy device, as well as advancing its innovative pipeline centered on NO release and generation technology.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=31804\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-15T05:04:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-15T05:05:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1502-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31804#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31804\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novlead Biotech Secures Series C Financing to Expand NO Inhalation Therapy Device Production\",\"datePublished\":\"2025-04-15T05:04:59+00:00\",\"dateModified\":\"2025-04-15T05:05:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31804\"},\"wordCount\":302,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31804#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1502-png.webp\",\"keywords\":[\"Finance\",\"Novlead Biotech\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31804#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31804\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=31804\",\"name\":\"Novlead Biotech Secures Series C Financing to Expand NO Inhalation Therapy Device Production - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31804#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31804#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1502-png.webp\",\"datePublished\":\"2025-04-15T05:04:59+00:00\",\"dateModified\":\"2025-04-15T05:05:00+00:00\",\"description\":\"Novlead Biotech, a Nanjing-based specialist in nitric oxide (NO) gas detection and treatment, has secured \\\"hundreds of millions\\\" of renminbi in a Series C financing round. Led by D&T Capital, the funding round included contributions from Yangzhou Guojin Investment, Zhongshan Investment Holding, Triwise Capital, Efung Capital, and Xingxiang Investment. The proceeds will be allocated toward expanding manufacturing capacity, commercial promotion, and overseas business development for its portable NO inhalation therapy device, as well as advancing its innovative pipeline centered on NO release and generation technology.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31804#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31804\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31804#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1502-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1502-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novlead Biotech Secures Series C Financing to Expand NO Inhalation Therapy Device Production\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31804#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novlead Biotech Secures Series C Financing to Expand NO Inhalation Therapy Device Production\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novlead Biotech Secures Series C Financing to Expand NO Inhalation Therapy Device Production - Insight, China's Pharmaceutical Industry","description":"Novlead Biotech, a Nanjing-based specialist in nitric oxide (NO) gas detection and treatment, has secured \"hundreds of millions\" of renminbi in a Series C financing round. Led by D&T Capital, the funding round included contributions from Yangzhou Guojin Investment, Zhongshan Investment Holding, Triwise Capital, Efung Capital, and Xingxiang Investment. The proceeds will be allocated toward expanding manufacturing capacity, commercial promotion, and overseas business development for its portable NO inhalation therapy device, as well as advancing its innovative pipeline centered on NO release and generation technology.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=31804","og_locale":"en_US","og_type":"article","og_title":"Novlead Biotech Secures Series C Financing to Expand NO Inhalation Therapy Device Production","og_description":"Novlead Biotech, a Nanjing-based specialist in nitric oxide (NO) gas detection and treatment, has secured \"hundreds of millions\" of renminbi in a Series C financing round. Led by D&T Capital, the funding round included contributions from Yangzhou Guojin Investment, Zhongshan Investment Holding, Triwise Capital, Efung Capital, and Xingxiang Investment. The proceeds will be allocated toward expanding manufacturing capacity, commercial promotion, and overseas business development for its portable NO inhalation therapy device, as well as advancing its innovative pipeline centered on NO release and generation technology.","og_url":"https:\/\/flcube.com\/?p=31804","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-15T05:04:59+00:00","article_modified_time":"2025-04-15T05:05:00+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1502-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=31804#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=31804"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novlead Biotech Secures Series C Financing to Expand NO Inhalation Therapy Device Production","datePublished":"2025-04-15T05:04:59+00:00","dateModified":"2025-04-15T05:05:00+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=31804"},"wordCount":302,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=31804#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1502-png.webp","keywords":["Finance","Novlead Biotech"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=31804#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=31804","url":"https:\/\/flcube.com\/?p=31804","name":"Novlead Biotech Secures Series C Financing to Expand NO Inhalation Therapy Device Production - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=31804#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=31804#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1502-png.webp","datePublished":"2025-04-15T05:04:59+00:00","dateModified":"2025-04-15T05:05:00+00:00","description":"Novlead Biotech, a Nanjing-based specialist in nitric oxide (NO) gas detection and treatment, has secured \"hundreds of millions\" of renminbi in a Series C financing round. Led by D&T Capital, the funding round included contributions from Yangzhou Guojin Investment, Zhongshan Investment Holding, Triwise Capital, Efung Capital, and Xingxiang Investment. The proceeds will be allocated toward expanding manufacturing capacity, commercial promotion, and overseas business development for its portable NO inhalation therapy device, as well as advancing its innovative pipeline centered on NO release and generation technology.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=31804#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=31804"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=31804#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1502-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1502-png.webp","width":1080,"height":608,"caption":"Novlead Biotech Secures Series C Financing to Expand NO Inhalation Therapy Device Production"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=31804#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novlead Biotech Secures Series C Financing to Expand NO Inhalation Therapy Device Production"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1502-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31804","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31804"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31804\/revisions"}],"predecessor-version":[{"id":31806,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31804\/revisions\/31806"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/31805"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31804"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31804"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31804"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}